In the age of semaglutide selfies and Ozempic “after” photos, personal trainers are facing a growing challenge: helping clients redefine the concept of transformation. It’s…
READ MORE
In the age of semaglutide selfies and Ozempic “after” photos, personal trainers are facing a growing challenge: helping clients redefine the concept of transformation. It’s…
READ MORE
As the fitness industry continues to evolve, personal trainers are increasingly becoming more than just exercise professionals; they are becoming essential members of multidisciplinary healthcare…
READ MORE
In the era of GLP-1 medications, it’s easy to fall into the trap of celebrating every pound lost. But if you’re a personal trainer working…
READ MORE
As I’ve mentioned up to this point in this series on GLP-1 agonist medications and fitness, we’re in a new era of body recomposition. The…
READ MORE
In the fast-moving world of metabolic medicine, GLP-1 receptor agonists (GLP-1 RAs) have earned a reputation as miracle molecules. Simply listen to any well-known podcaster…
READ MORE
Based on recent articles in this series, GLP-1 receptor agonists have emerged as a promising pharmaceutical option for individuals dealing with the complexities of…
READ MORE
There’s a question more and more personal trainers are starting to hear at the end of a training session or over coffee after a client…
READ MORE
In the era of GLP-1 receptor agonists (GLP-1 RAs), personal trainers face a new wave of clients experiencing rapid weight loss, but not always in…
READ MORE
As the popularity of GLP-1 receptor agonists (GLP-1 RAs) continues to surge, particularly among clients seeking medically supported weight loss, personal trainers must evolve their…
READ MORE
If you’re a personal trainer working with clients on GLP-1s like Ozempic, Wegovy, or Mounjaro, it’s essential you understand one unassailable truth: you’re not just…
READ MORE
Per the first article of this series, the emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed clinical care for individuals with obesity and…
READ MORE
The rapid adoption of GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide (Ozempic, Wegovy) has revolutionized the treatment of type 2 diabetes and obesity. However,…
READ MORE